Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast01: Dato-DXd vs Chemotherapy in HR+/HER2- Breast Cancer
NCT05104866Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of datopotamab deruxtecan in breast cancer, sponsored by AstraZeneca. Started Oct 2021; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05104866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104866.